⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Syremis Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Syremis Therapeutics
↗Petah Tiqwa, Israel
Syremis Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel, best-in-class medicines for mental health conditions, including schizophrenia, major depressive disorder, and bipolar depression. The company utilizes clinically validated mechanisms, specifically muscarinic M1/M4 agonism and next-generation NMDA receptor antagonism, to create more effective and better-tolerated treatments.
Formed as a spin-out from Clexio Biosciences in 2025, the company is backed by a syndicate of prominent venture capital firms and strategic investors. Syremis operates with a focus on neuropsychiatric drug development, leveraging the expertise of industry veterans to advance its pipeline toward Phase 2 proof-of-concept studies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$165M
Investors:Dexcel Pharma, Third Rock Ventures, Bain Capital Life Sciences, Google Ventures (GV), QVT, Pictet
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Small molecule
Active Trials:0
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Clexio Biosciences (Originator/Spin-out partner)
COMPETITION
Position:Emerging
Competitors:Karuna Therapeutics (BMS), MapLight Therapeutics
LEADERSHIP
Key Executives:
Elisabeth Kogan - CEO and Co-Founder
Elena Kagan - Chief Development Officer and Co-Founder
Menashe Levy - Chief Technology Officer and Co-Founder
Steve Paul - Board Member / Co-Founder
Scientific Founders:Elisabeth Kogan, Elena Kagan, Menashe Levy, Steve Paul
Board Members:Steve Paul
LINKS
Website:syremis.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Syremis Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.